Shanghai Junshi Biosciences Announces Reorganization

Shanghai Junshi Biosciences Co., Ltd. Class H (HK:1877) has released an update.

Shanghai Junshi Biosciences has announced a reorganization involving the sale of about 9.45% equity interest in Shanghai Allink to Allink Hong Kong, and the subscription to a Warrant for a similar equity percentage in Allink Cayman. The deal, valued at RMB 30,597,800, is part of a broader Reorganization Framework Agreement, which is subject to reporting and announcement requirements but exempt from shareholder approval under Hong Kong Listing Rules.

For further insights into HK:1877 stock, check out TipRanks’ Stock Analysis page.